Inflammatory Treatment Articles & Analysis
38 news found
To address this need, Protheragen-ING continues to prove itself as a top supplier of nonsteroidal anti-inflammatory APIs (NSAIDs), a class of anti-inflammatory APIs. These widely used compounds are helpful to manage various inflammatory conditions such as arthritis, musculoskeletal injuries, toothaches, menstrual pain and headaches. ...
The implementation of AIR will aid in the recruitment of patients for clinical trials focused on inflammatory bowel disease (IBD). Both One GI® and Iterative Scopes are fast-growing innovators in the gastroenterology space. ...
“We are all united by our ultimate mission of bringing world-class care and treatment to patients around the world, and we strive to foster a culture that encourages collaboration and visionary thinking to help us drive our innovation ...
“Clinical trials are extremely important to the development of new treatment methods for patients with IBD, and we look forward to contributing to this advancement by expanding and optimizing our clinical research ...
About Iterative Health Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD) and improving the accuracy of colorectal cancer screenings. ...
(“BRIM,” TPEx 6885) announced today that it has officially submitted the Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease (DED) to the U.S. Food and Drug Administration (FDA). ...
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted PRAC’s recommendation to add measures to minimise risk of serious side effects with JAK inhibitors for chronic inflammatory disorders. “JAK inhibitors are an important ...
Q3 2022 operational review and recent events Jyseleca commercial & regulatory progress Strong adoption across Europe with reimbursement for rheumatoid arthritis (RA) in 15 countries and for ulcerative colitis (UC) in 10 countries Marketing Authorization Application (MAA) submitted for the treatment of UC to Swissmedic, the regulatory authority in Switzerland Article ...
AI Recruitment (AI-R) addresses clinical trial recruitment pain points for pharmaceutical companies and clinical research teams working to surface eligible patients for inflammatory bowel disease (IBD) clinical trials. Recruiting qualified patients is one of the most significant and expensive challenges of clinical trials, but AI-R helps determine if patients are qualified for ...
About Iterative Scopes Iterative Scopes is a pioneer in the application of artificial intelligence-based precision medicine for gastroenterology with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD). The technology is also designed to potentially enhance colorectal cancer screenings. ...
Patients whose lungs have untreated collateral ventilation (CV+) are currently ineligible for treatment with Zephyr Valves and have limited options once medical management alone does not control symptoms. ...
About VE202 VE202 is a first-in-class defined bacterial consortium therapeutic candidate for the treatment of inflammatory bowel disease (IBD). It consists of 16 bacterial strains of the Clostridia class that were rationally selected. ...
£1 million grant will support first-in-human clinical trials of H-Guard Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening ...
In the past decade, pharmaceutical companies have been reluctant to re-address pain treatments following the opioids crisis. However, we see a change on the horizon. Neuropathix has designated proprietary, cannabinoid-derivative compound KLS-13019 as lead drug candidate for the treatment of neuropathic pain, a viable alternative to opioids. Neuropathix wholly ...
These medicine products for the treatment of cancer are on the WHO Model List of Essential Medicines. The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication. Most other biosimilar treatments, particularly in oncology, create a high-cost burden on the payer or patient and often are ...
About Siolta Therapeutics Siolta Therapeutics is a clinical-stage biopharmaceutical company developing novel microbiome-based targeted therapeutics for the prevention and treatment of inflammatory, chronic, and life-threatening diseases. STMC-103H, currently in Phase 1b/2 development in the US (NCT05003804), is designed to trigger tolerant immunological ...
LYR-210 is designed to be administered in a brief, non-invasive, in-office procedure and deliver up to six months of continuous anti-inflammatory medication to the sinonasal passages. "LYR-210 is the first product candidate designed to provide six months of continuous therapy with a single treatment and represents a significant opportunity to introduce a new ...
1 Establishment of new drug pipeline with bilirubin platform technology Securing global competitiveness by increasing corporate value “I want to give hope to those who are living a difficult life with an incurable disease” [IB Tomato Lim Seong-ji] “The new drug development industry is a specialized area that is difficult for ordinary investors and shareholders to understand, ...
Myung-Rip Kim, CEO of Vilix said, “The research team led by Professor Sang-Yong Jeon of KAIST’s research team has proven the effectiveness of treatment in eight animal models of eight types of disease as a way to solve the hydrophobicity of bilirubin over the past 7 years, and based on this, the publication was ...
GALWAY, Ireland–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced Food and Drug Administration (FDA) clearance of its proprietary NEUROMARK™ Rhinitis Neurolysis Therapy™ (RNT). ...